Newer Therapeutic Targets in Head and Neck Cancers
A Cohort Study to Identify Newer Therapeutic Targets in Head and Neck Cancers
1 other identifier
observational
200
1 country
1
Brief Summary
Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes:
- 1.cellular survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA);
- 2.cell-cycle control (e.g., CDKN2A and CCND1);
- 3.cellular differentiation (e.g., NOTCH1); and
- 4.Adhesion and invasion signaling (e.g., FAT1).7 TP53, EGFR, PIK3CA, CDKN2A, CCND1, and MET participate in several common signaling pathways.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2017
CompletedFirst Submitted
Initial submission to the registry
May 16, 2022
CompletedFirst Posted
Study publicly available on registry
May 19, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
August 13, 2024
August 1, 2024
10.8 years
May 16, 2022
August 9, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Over all survival
Survival time from the diagnosis to death
10 years
Relapse free survival
survival time from diagnosis to recurrence or metastasis
10 years
Secondary Outcomes (1)
Progression free survival
5 years
Study Arms (1)
Head neck cancer
Histologically diagnosed cases of head and neck cancer
Interventions
Eligibility Criteria
Histologically proven cases of Head and neck cancer undergoing treatment will be included, Next generation sequencing will be done and cohort will be followed up for 10 years
You may qualify if:
- Histologically proven cases of primary head and neck cancers.
You may not qualify if:
- Patients under 18 years of age
- Pregnant and lactating women
- Multiple cancers or patients with cancer of other sites.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Banaras Hindu University
Varanasi, Uttar Pradesh, 221005, India
Related Publications (1)
Batta N, Pandey M. Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance. World J Surg Oncol. 2019 Nov 27;17(1):198. doi: 10.1186/s12957-019-1741-2.
PMID: 31775759RESULT
Biospecimen
Paraffin embedded tissue
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Manoj Pandey, MS, PhD
Professor
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 16, 2022
First Posted
May 19, 2022
Study Start
April 1, 2017
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
August 13, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- 6 months
- Access Criteria
- On request
On request